PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Remission Induction”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1978

Remission induction in chronic granulocytic leukaemia using intermittent high-dose busulphan.

In a series of 19 patients, the pre-blastic phase of chronic granulocytic leukaemia was controlled with busulphan given as single doses of 50-100 mg at 2-weekly intervals. Although there was no significant increase in the incidence of Ph1-negative cells in the bone marrow, remissions of a better haematological quality were attained more rapidly than with conventional therapy.

Busulfan↗
PubMed1997

Blood bank leukocyte infusions as remission induction therapy in a case of acute lymphoblastic leukemia.

A 15-year-old female with pre-pre B ALL in third relapse was treated with administration of eight blood bank leukocyte concentrates per day for 5 days. The total number of mononuclear cells per kilogram of weight was 4.89 x 10(8). On the fifth day of infusions the patient was in complete remission (CR), asymptomatic and with a normal CBC. No secondary effects were found. The patient remained in CR without treatment for 10 weeks before relapsing again. The possibility of reaching a short-lived, clinically relevant response, using blood bank leukocyte infusions, is a promising new approach for the treatment of leukemia.

Adolescent↗
PubMed1976

Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone.

Therapy for acute lymphocytic leukemia (ALL) has been less successful in adults than in children. Many centers treat all adult leukemia with the same regimen. We have used vincristine and prednisone for initial therapy in 14 adults with ALL since 1971 and have followed a treatment regimen developed for childhood ALL for subsequent therapy as well. Complete remissions were attained in 13, and complications and duration of hospitalization were minimized with this nonmyelotoxic regimen. Central nervous system "prophylactic" therapy was also well tolerated in these adult patients. However, remission duration and survival in our series were similar to those reported by others. That complete remission can be attained in a high percentage of adult patients with ALL through use of relatively nontoxic treatment demonstrates the importance of selecting out this group of patients from all adults with acute leukemia.

Adolescent↗
PubMed1984

In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia.

Fifty-three adult patients who presented with previously untreated acute leukemia had leukemic cells incubated in vitro with five doses of cytosine arabinoside (0.001-0.1 microgram/ml) and adriamycin (0.1-10 microgram/ml). Thymidine incorporation was measured in treated and untreated cells. Greater than 80% suppression of pretreatment thymidine incorporation after treatment with 0.004 micrograms/ml of cytosine arabinoside correlated with complete remission (CR) of the patient. A Mahalanobis' D2 score, which provides an index of the deviation of patient's in vitro drug response from the mean profile of responders, was calculated for each drug. Patients who had D2 values greater than 10 for Ara-C were less likely to respond to therapy. Patients with low D2s had rates of CR higher than predicted by the prognostic model employed at U.T.M. D. Anderson Hospital. However, unlike in our previous report, responders and non-responders were not clearly separable on the basis of the D2 value.

Adolescent↗
PubMedDate not supplied

Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).

Twenty nine consecutive patients (pts) with either relapsed (n = 23) or primary refractory AML (n = 6) were treated with 1 or 2 cycles of intermediate-dose (ID) ara-C (1g/m2 IV q 12 h days 1-6) and m-AMSA (120 mg/m2 IV days 5-7). Pts reaching complete remission (CR) were consolidated with 1 cycle of ara-C 3 g/m2 IV q 12 h days 1-4 and m-AMSA 120 mg/m2 IV day 5. The median duration of the preceding remission was 9.5 months, median time from last chemotherapy until relapse 3 months. 18/23 (78%) of relapsed pts achieved CR regardless of the type of prior intensive maintenance (HD-ara-C/m-AMSA/5-AZA or DNR/CD-ara-C). 3/23 (13%) pts died during hypoplasia, 2/23 (9%) pts were refractory to 2x ID-ara-C/m-AMSA. 3/23 pts died in CR during hypoplasia after intensive consolidation with HD-ara-C. Predictive factors for remission were the duration of preceding remission and the time from last chemotherapy to relapse. Three pts were transplanted in 2nd CR. 1/6 refractory pts reached CR, 2 pts remained refractory, and 3 died during hypoplasia. The median duration of disease-free survival (DFS) of relapsed pts was 3.3 months without further treatment, median survival of responding pts (18 replased pts, 1 refractory pt) was 4.6 months, the overall survival (n = 29) was 4.8 months. Pts receiving BMT were censured at the time of BMT. Seven pts experienced lung toxicity due to ara-C, four of whom died. The incidence of lung toxicity was clearly related to the extent of ara-C pretreatment during intensive maintenance. In conclusion, ID-ara-C/m-AMSA is a very effective reinduction treatment in these pts with acceptable toxicity; the impact of HD-ara-C during consolidation for DFS and survival is questionable.

Adolescent↗
PubMed1980

Remission-induction regimens in acute nonlymphocytic leukemia.

A sequential study was carried out involving 40 adults with acute nonlymphocytic leukemia (ANLL). The first 20 patients were treated with cytarabine (Ara-C) and 6-thioguanine (6-TG), the second 20 with a regimen that added a three-day course of daunomycin (DNM) to the Ara-C and 6-TG therapy. With both groups well matched for age, patients in the DNM-treated group had a higher complete remission (CR) rate but failed to survive longer than those in the Ara-C and 6-TG treatment group. In a comprehensive literature review of various treatments for adult ANLL, a higher CR rate but not significantly better survival for patients initially treated with DNM-combined regimens was found. Our analysis of cases and literature review suggest that while DNM is a very active drug, its use in the initial treatment of adult ANLL has not produced a significant improvement in overall survival or in survival of those brought into complete remission.

Aged↗